8-K: Viemed Healthcare to Acquire Lehan Drugs for $26 Million, Expanding into Women's Health

Viemed Healthcare announces a definitive agreement to acquire Lehan Drugs, Inc., a home medical equipment provider, for a base purchase price of $26 million, diversifying its product mix into maternal health.

Summary

• Viemed Healthcare, Inc. has entered into a definitive agreement to acquire Lehan Drugs, Inc., a privately held provider of home medical equipment.
• The base purchase price is $26 million, subject to customary adjustments for net working capital and an estimated $2.2 million of contingent payments.
• Lehan Drugs, based in DeKalb, Illinois, generated approximately $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024.
• The acquisition is expected to close in the third quarter of 2025, pending satisfaction of closing conditions.
• Viemed intends to fund the acquisition through a combination of cash on hand and borrowings from its existing credit facilities.
• The acquisition will diversify Viemed's product mix into maternal health, specifically women's health products like breast pumps.
• Lehan has three full-service locations in Northern Illinois and three sleep/CPAP set up locations in the West Chicagoland area, including one in Wisconsin.
• Owners Jim and Jon Lehan and the more than 90 employees of the organization will join Viemed upon the completion of the transaction.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a strategic acquisition that diversifies Viemed's business and expands its market reach. The financial metrics of the acquired company are solid, and management expresses confidence in the integration. However, there are inherent risks associated with acquisitions, which temper the overall sentiment.

Positives

• The acquisition diversifies Viemed's product mix into the growing maternal health market.
• Lehan has a strong presence in Northern Illinois and the West Chicagoland area with six locations.
• Lehan generated $7.4 million in Adjusted EBITDA in 2024.
• Lehan has a long-standing reputation and brand equity, operating for nearly 80 years.
• The acquisition provides Viemed with a platform to execute its growth strategy in a large and fast-growing market.

Risks

• The closing of the acquisition is subject to the satisfaction of closing conditions, which may not be met.
• Integration of Lehan's operations and employees into Viemed may present challenges.
• The forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Viemed expects the acquisition to expand its presence in the home medical equipment market and diversify its product mix into maternal health. The company anticipates funding the acquisition through a combination of cash on hand and borrowings from its existing credit facilities.

Management Comments

• Viemed Chief Executive Officer Casey Hoyt stated that Lehan gives Viemed a strong platform to execute its growth strategy in a large and fast-growing market.
• Casey Hoyt also noted that the acquisition diversifies Viemed's product mix into maternal health that they expect to extend to their existing payer relationships across the country.

Industry Context

The acquisition reflects a trend of consolidation in the home medical equipment industry, as companies seek to expand their geographic reach and product offerings. Viemed's move into maternal health aligns with the growing demand for specialized healthcare services in the home.

Comparison to Industry Standards

• The acquisition multiple of approximately 3.5x Lehan's 2024 Adjusted EBITDA ($26 million / $7.4 million) appears to be within the typical range for acquisitions in the home medical equipment sector.
• Comparable companies in the home medical equipment space, such as AdaptHealth and Rotech Healthcare, have also pursued acquisitions to expand their market presence and service offerings.
• The expansion into women's health mirrors trends seen with other healthcare providers looking to diversify service offerings to capture a broader patient base.

Stakeholder Impact

• Shareholders may view the acquisition positively, as it diversifies Viemed's revenue streams and expands its market presence.
• Lehan's employees will become part of Viemed, potentially benefiting from the resources and opportunities of a larger organization.
• Customers of both Viemed and Lehan may benefit from a broader range of products and services.

Next Steps

• The transaction is subject to customary closing conditions.
• Viemed expects to close the acquisition in the third quarter of 2025.
• Viemed will integrate Lehan's operations and employees into its existing business.

Key Dates

Keywords

acquisition, Viemed Healthcare, Lehan Drugs, home medical equipment, maternal health, respiratory care, Adjusted EBITDA